Product Name:

TrkC-pY709+pY710


Product Number:

ab-pk840

Price:

Regular price
$98.00
Regular price
Sale price
$98.00

Download Product PDF

Target Full Name: Neurotrophin 3 (NT-3) growth factor receptor

Target Alias: GP145-TrkC; Kinase TrkC; Neurotrophic tyrosine kinase receptor 3; Neurotrophic tyrosine kinase, receptor, type 3; Neurotrophin-3 receptor non-catalytic isoform 1; NT-3 growth factor receptor; NTrk3; TrkC; TrkC tyrosine kinase; gp145(trkC); CCDS10340.1; ENSG00000140538

Product Type Specific: TrkC protein kinase phosphosite-specific antibody

Antibody Code: PK840

Antibody Target Type: Phosphosite-specific

Antibody Phosphosite: Y709+Y710

Protein UniProt: Q16288

Protein SigNET: TrkC

Antibody Type: Polyclonal

Antibody Host Species: Rabbit

Antibody Immunogen Source: Human TrkC (NTrk3) sequence peptide Cat. No.: PE-04AHW95

Antibody Immunogen Sequence: STD(pY)(pY)RLF(bA)C

Antibody Immunogen Description: Corresponds to amino acid residues S706 to F713; in the protein kinase catalytic domain activation T loop region between subdomains VII and VIII. Y709 and Y710 phosphorylation is predicted to be stimulatory for phosphotransferase activity. This are major sites of phosphorylation for TrkC based on ≥30 and ≥9 high throughput mass spectrometry reports, respectively, recorded in PhosphoSitePlus. TrkC is known to be phosphorylated at this site in vitro by Y709 and Y710 by TrkC (NTRK3).

Production Method: The immunizing peptide was produced by solid phase synthesis on a multipep peptide synthesizer and purified by reverse-phase hplc chromatography. Purity was assessed by analytical hplc and the amino acid sequence confirmed by mass spectrometry analysis. This peptide was coupled to KLH prior to immunization into rabbits. New Zealand White rabbits were subcutaneously injected with KLH-coupled immunizing peptide every 4 weeks for 4 months. The sera from these animals was applied onto an agarose column to which the immunogen peptide was thio-linked. Antibody was eluted from the column with 0.1 M glycine, pH 2.5. Subsequently, the antibody solution was neutralized to pH 7.0 with saturated Tris.

Antibody Modification: Unconjugated. Contact KInexus if you are interest in having the antibody biotinylated or coupled with fluorescent dyes.

Antibody Concentration: 0.5 mg/ml

Storage Buffer: Phosphate buffered saline pH 7.4, 0.05% Thimerasol

Storage Conditions: For long term storage, keep frozen at -40°C or lower. Stock solution can be kept at +4°C for more than 3 months. Avoid repeated freeze-thaw cycles.

Product Use: Western blotting | Antibody microarray

Antibody Dilution Recommended: 2 µg/ml for immunoblotting

Antibody Potency: Medium immunoreactivity with immunogen peptide on dot blots.

Antibody Species Reactivity: This antibody detects the target phosphoprotein in the following species due to conservation of amino acid sequence: Human | Rhesus Macaque | Dog | Rat | Mouse | Platypus | Chicken | Frog | Zebra fish | Fruit fly.

Antibody Positive Control: The observed molecular mass of the processed target protein on SDS-PAGE gels is reported to be around 90-110 kDa.

Antibody Specificity: High-very high

Antibody Cross Reactivity: No significant cross-reactive proteins in T98G cells.

Scientific Background: TrkC is one of several protein kinases that can phosphorylate KinSub1DDLYF. TrkC is a receptor protein-tyrosine kinase that is a member of the TK group of protein kinases in the Trk family. This kinase shows high variability in human tissue distribution with the highest levels detected in brain, liver, spinal cord and thymus. It is the high affinity catalytic receptor for the neurotrophin NT-3. TrkC is activated by phosphorylation at Y516. Phosphorylation of Y834 of TrkC induces interaction with PLCg1 and Shc1. TrkC mediates the multiple cellular effects of the NT-3 neurotrophic factor, which includes neuronal differentiation and survival. TrkC has been implicated in insulin signalling pathway through interactions with the MUSK protein receptor and the VEGF receptor. Mutations in the TrkC gene have been associated with medulloblastomas, secretory breast carcinomas and other cancers. TrkC has also been linked with the development of pediatric mesenchymal, colon, and large lung cell carcinomas (LLCC), and gastric and lung adenocarcinomas. This description may include information annotated by UniProt and/or Google AI.